Latest Research
All publications from the Cancer3.AI database, newest first.
Comparative study of approached cancer incidence in a cohort of permanent nuclear workers with that in a sample of French population, period 2009-2018.
Baudin C, et al
A French study examined cancer incidence among 27,473 permanent nuclear workers at Électricité de France who had been monitored for ionizing radiation exposure, comparing their rates to a representative sample of over 611,000 members of the general French population using national health administrative data from 2009 to 2018. Researchers used validated diagnostic algorithms applied to the National Health Data System (SNDS) to estimate cancer rates, as no comprehensive national cancer registry exists in France. The study found significantly higher incidence of prostate cancer, malignant melanoma of the skin, and breast cancer in women among nuclear workers compared to the general population, while deficits were observed for liver, larynx, lung, and bladder cancers. The elevated rates may partly reflect the so-called 'healthy worker effect' and better access to medical screening rather than direct radiation causality, and the authors caution that individual radiation dose data were not yet linked to the findings. This research represents the first use of the SNDS database to assess cancer incidence in an occupational cohort, laying the groundwork for future exposure-risk analyses once full data access is available. The findings are important for occupational health monitoring and for understanding cancer risk in radiation-exposed workers.
Environmental research
Source →A perspective on precision therapeutics in polycystic ovary syndrome: integrating multi-omics, AI-driven stratification, and emerging biologics.
Pinton P
A new perspective article published in Frontiers in Endocrinology calls for a fundamental shift in how polycystic ovary syndrome (PCOS) is treated, arguing that the current one-size-fits-all approach fails to address the disorder's profound biological heterogeneity. The authors propose integrating multi-omics profiling — encompassing genomics, proteomics, and metabolomics — with artificial intelligence-driven patient stratification to identify distinct molecular subtypes of PCOS and match patients to therapies most likely to benefit them. Among the emerging therapeutic strategies highlighted are anti-Müllerian hormone (AMH) neutralization, neuroendocrine modulators targeting the hormonal dysregulation underlying the syndrome, and next-generation biologic agents that go beyond symptomatic management to address root disease mechanisms. The authors also address the regulatory, ethical, and operational challenges that must be overcome to translate these scientific advances into approved treatments for patients. For the millions of women affected by PCOS-related reproductive, metabolic, and psychological complications, this precision medicine roadmap offers a scientifically grounded path toward more effective and individualized care.
Frontiers in endocrinology
Source →Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.
Jeng A, et al
A new study published in the Annals of Surgical Oncology examined national trends in the use of accelerated partial-breast irradiation (APBI) for patients with ductal carcinoma in situ (DCIS) — a non-invasive form of early breast cancer — treated with breast-conserving surgery between 2011 and 2021. Researchers analyzed data from the National Cancer Database to assess how clinical practice changed following the 2017 update by the American Society for Radiation Oncology, which broadened the criteria for recommending APBI to include older patients with smaller, lower-grade tumors and adequate surgical margins. The study found that APBI utilization nearly doubled, rising from 7.2% before the guideline update to 13.0% afterward, with even higher adoption rates among patients who specifically met the new eligibility criteria. Key factors associated with greater APBI use included age 50 or older, treatment at academic medical centers, low- to intermediate-grade tumors, tumor size of 25 mm or smaller, and estrogen receptor-positive disease. These findings demonstrate that the 2017 consensus guidelines have meaningfully influenced clinical practice, encouraging more widespread use of a shorter, more targeted radiation approach that can reduce treatment burden for appropriately selected DCIS patients.
Annals of surgical oncology
Source →Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.
Dai Y, et al
Researchers conducted a systematic review and network meta-analysis to evaluate the efficacy and safety of antibody-drug conjugates (ADCs) — a class of targeted cancer therapies that deliver chemotherapy directly to tumor cells — in patients with locally advanced or metastatic urothelial carcinoma, a difficult-to-treat bladder and urinary tract cancer. Analyzing 30 studies involving 3,631 patients published up to September 2025, the team found that the ADC enfortumab vedotin combined with the immunotherapy pembrolizumab significantly outperformed standard treatments, reducing the risk of death by 37% and cutting the risk of disease progression by 52%. Among emerging regimens evaluated in single-arm trials, the combination of bulumtatug fuvedotin with toripalimab achieved a remarkable objective response rate of 88%, meaning nearly nine in ten patients showed measurable tumor shrinkage. Disitamab vedotin-based combinations demonstrated the longest median overall survival among the therapies analyzed. While ADC-based therapies were associated with higher rates of serious side effects compared to standard care, the authors conclude that their benefit-risk profile is favorable and that these agents represent a major advance for patients with limited options. The findings highlight the urgent need for further clinical trials to optimize personalized treatment strategies in this aggressive cancer setting.
Frontiers in immunology
Source →Quality of life and symptoms in acute myeloid leukaemia with early palliative care: real-world observational study.
Potenza L, et al
Researchers conducted a prospective observational study to evaluate how quality of life (QOL) and symptom burden change over time in patients with acute myeloid leukaemia (AML) who received early palliative care (EPC) in a real-world outpatient clinic setting during the first year after diagnosis. Thirty-eight patients were followed monthly using validated tools measuring overall QOL, physical symptoms, and anxiety and depression. The findings revealed significant and sustained improvements in both QOL scores and symptom burden within four months of starting EPC, with these gains maintained through twelve months. Anxiety showed a modest improvement, though changes in anxiety and depression scores did not reach statistical significance. These results suggest that integrating palliative care early into routine AML management can meaningfully benefit patients by reducing symptom burden and improving quality of life, even outside of controlled clinical trial settings. The study provides valuable real-world reference data to support the design of future randomized controlled trials examining EPC in leukemia care.
BMJ supportive & palliative care
Source →